Federal regulators’ approval of Amgen Inc.’s bone drug denosumab for the treatment of bone complications in cancer patients now opens the door to a large and lucrative oncology market that analysts widely expect to exceed $1 billion in annual sales for the biotech giant....

Join our Membership to get the full story.


Are you a current Member? Sign In